Journal of the American Academy of Child & Adolescent Psychiatry
ReviewNeurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials
Section snippets
Method
The EAGG protocol was originally registered on the International Prospective Register of Systematic Reviews (PROSPERO; http://www.crd.york.ac.uk/PROSPERO, protocol number: CRD42011001393). As in previous work,4, 5 the original protocol was adapted to take account of the broader scope of this systematic review/meta-analysis. Most crucially, given that the scope of this analysis included neuropsychological measures, the mandatory requirement for studies to have ADHD symptoms-related outcomes no
Results
A total of 13 trials24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 met entry criteria. Figure 1 presents the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) selection flowchart. Table S1, available online, provides a list of excluded papers with reasons for exclusion. Retained studies included a total of 520 participants with ADHD. Table 1 gives information about the characteristics of the retained trials. Table 2 summarizes results of all analyses. There were
Discussion
The rationale for the use of neurofeedback for ADHD rests on the idea that promoting normalization or self-regulation of brain activity will translate into improved cognitive and behavioral control that is deficient in individuals with ADHD. A previous meta-analysis17 based on a limited number of trials (n = 8) was inconclusive with regard to the efficacy of neurofeedback for ADHD symptoms. Although there were moderate but highly significant effects (SMD = 0.59; 95% CI = 0.31−0.87) for ADHD
References (48)
- et al.
Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials
J Am Acad Child Adolesc Psychiatry
(2015) - et al.
Neurofeedback for ADHD: a review of current evidence
Child Adolesc Psychiatr Clin North Am
(2014) - et al.
A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder
Clin Psychol Rev
(2009) - et al.
Evaluation of neurofeedback in ADHD: the long and winding road
Biol Psychol
(2014) - et al.
Training of slow cortical potentials in attention-deficit/hyperactivity disorder: evidence for positive behavioral and neurophysiological effects
Biol Psychiatry
(2004) - et al.
Comparing tomographic EEG neurofeedback and EMG biofeedback in children with attention-deficit/hyperactivity disorder
Biol Psychol
(2014) - et al.
Neurofeedback in children with ADHD: specific event-related potential findings of a randomized controlled trial
Clin Neurophysiol
(2011) - et al.
Attention-deficit/hyperactivity disorder
Nature Reviews: Disease Primers
(2015) - et al.
Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents
J Child Psychol Psychiatry
(2015) Uses and misuses of treatments for ADHD. The second Birgit Olsson lecture
Nord J Psychiatry
(2014)
Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains
J Am Acad Child Adolesc Psychiatry
A systematic review of meta-analyses of psychosocial treatment for attention-deficit/hyperactivity disorder
Clin Child Fam Psychol Rev
Research review: The role of diet in the treatment of attention-deficit/hyperactivity disorder—an appraisal of the evidence on efficacy and recommendations on the design of future studies
J Child Psychol Psychiatry
Editorial: Neurofeedback in ADHD
Front Hum Neurosci
EEG and behavioral changes in a hyperkinetic child concurrent with training of the sensorimotor rhythm (SMR): a preliminary report
Biofeedback Self Regul
A decade of EEG theta/beta ratio research in ADHD: a meta-analysis
J Atten Disord
Commentary: Persistent time estimation deficits in ADHD? From developmental trajectories to individual targets for intervention—reflections on Doehnert et al. (2013)
J Child Psychol Psychiatry
A neurophysiological marker of impaired preparation in an 11-year follow-up study of attention-deficit/hyperactivity disorder (ADHD)
J Child Psychol Psychiatry
Meta-analysis of attention-deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives
J Am Acad Child Adolesc Psychiatry
Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity: a meta-analysis
Clin EEG Neurosci
Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments
Am J Psychiatry
EEG neurofeedback treatments in children with ADHD: an updated meta-analysis of randomized controlled trials
Front Hum Neurosci
Cited by (192)
Remote neurocognitive interventions for attention-deficit/hyperactivity disorder – Opportunities and challenges
2023, Progress in Neuro-Psychopharmacology and Biological PsychiatryInterventions for ADHD in childhood and adolescence: A systematic umbrella review and meta-meta-analysis
2023, Clinical Psychology ReviewComplementary and Integrative Treatments for Attention-Deficit/Hyperactivity Disorder in Youth
2023, Child and Adolescent Psychiatric Clinics of North America
European ADHD Guidelines Group (EAGG) Members: Phil Asherson, MBBS, MRPsych, PhD, Tobias Banaschewski, MD, PhD, Daniel Brandeis, PhD, Jan Buitelaar, MD, PhD, David Coghill, MD, Samuele Cortese, MD, PhD, David Daley, PhD, Marina Danckaerts, MD, PhD, Ralf W. Dittmann, MD, PhD, Manfred Döpfner, PhD, Maite Ferrin, MD, PhD, Chris Hollis, MD, PhD, Martin Holtmann, MD, PhD, Eric Konofal, MD, PhD, Michel Lecendreux, MD, Aribert Rothenberger, MD, Paramala Santosh, MD, PhD, Joseph A. Sergeant, PhD, Emily Simonoff, MD, Edmund J. Sonuga-Barke, PhD, Cesar Soutullo, MD, HansChristoph Steinhausen, MD, PhD, Jim Stevenson, PhD, Argyris Stringaris, MD, PhD, MRCPsych, Eric Taylor, MD, Saskia van der Oord, PhD, Ian Wong, PhD, and Alessandro Zuddas, MD.
Support for meetings and analyses was received from Brain Products GMBH, Janssen-Cilag, Eli Lilly and Co., Medice, Shire, and Vifor. No honoraria were received, and funders had no input into the review and meta-analysis process or the writing of the paper.
Drs. Cortese and Ferrin are joint first authors.
Disclosure: Dr. Cortese has received grant or research support from the Solent National Health Service (NHS) Trust, UK. He has received honorarium and travel expenses from the Association for Child and Adolescent Mental Health (ACAMH), UK. Dr. Ferrin was invited to participate to give a workshop on “Behavioural Interventions in ADHD” at the Meeting of Minds, Stockholm 2015, organized by Shire. Dr. Brandeis has served as an unpaid scientific advisor for a European Union (EU)-funded neurofeedback trial. Dr. Holtmann has served in an advisory or consultancy role for Medice and Shire, and has received conference attendance support or was paid for public speaking by Eli Lilly and Co., Medice, Neuroconn, and Shire. Dr. Daley has provided educational talks for Eli Lilly and Co. and Shire, has attended an advisory board for Eli Lilly and Co., has received support for educational travel from Eli Lilly and Co., Shire, and HP Pharma, and research funding from Shire. He has received royalties from the sale of a self-help version of the New Forest Parenting Programme. Dr. Santosh has received research funding from the EU (FP7 Programme) and the National Institute for Health Research (NIHR). He is a director and shareholder of HealthTracker, Ltd., UK, and HighStreet Medical Dental, Gillingham, UK. Dr. Simonoff has received grant funding from the following sources: NIHR; Autism Speaks; European Innovative Medicines Initiative; Wellcome Trust; South London and Maudsley Charitable Foundation; Biomedical Research Centre Nucleus Pilot Funding; NIHR Evaluation, Trials and Coordinating Centre (NETSCC). Dr. Stringaris has received grant or research support from the Guy’s and St. Thomas’ Charity, the Wellcome Trust, NIHR, and University College London for a joint project with Johnson and Johnson. He has received royalties from Cambridge University Press for The Maudsley Reader in Phenomenological Psychiatry and Oxford University Press for Disruptive Mood: Irritability in Children and Adolescents. Dr. Sonuga-Barke has received research funding and conference support from Shire Pharma; has received speaker fees from Shire Pharma, Janssen-Cilag, and Medice; has received book royalties from Oxford University Press and Jessica Kingsley; has served as a consultant to Shire Pharma, Neurotech Solutions, Aarhus University, Copenhagen University, and KU Leuven. Dr. Stevenson and Mr. Aggensteiner report no biomedical financial interests or potential conflicts of interest.